Fairvalue-Calculator Fairvalue-Calculator
EN DE

MedPacto, Inc (235980) Fair Value & Analysis

Healthcare · KR · Market cap 117B KRW

Price3,060 KRW
Fair Value2,415 KRW
Upside-21.1%
Quality95/100
Evidence: Low Range 1,811 KRW – 3,019 KRW

Fair value as of: Jun 24, 2026

Analysis

MedPacto, Inc (235980) currently trades at 3,060 KRW, while our model-based Fair Value estimate is 2,415 KRW — implying the stock looks roughly 21.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MedPacto, Inc. engages in the development and sale of marker-based new drugs in South Korea. MedPacto, Inc. was established in 2013 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is MedPacto, Inc (235980) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 2,415 KRW versus a price of 3,060 KRW — about −21% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 235980?
Our 21-model fair value for MedPacto, Inc is 2,415 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,060 KRW.
What is the quality score of 235980?
MedPacto, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.